Skip to main content
Clinical Trials/NCT02297399
NCT02297399
Completed
Phase 3

Improvement of Tolerability for Bowel Preparation for Colonoscopy in Diabetic Patients. A Randomized Controlled Trial of Two Bowel Preparation Protocols Including 4 Liters PEG vs. 2 Liters PEG Plus Ascorbic Acid. iDIMEPREP Study.

Parc de Salut Mar2 sites in 1 country158 target enrollmentDecember 2, 2014

Overview

Phase
Phase 3
Intervention
PEG-ascorbate 2L
Conditions
Diabetes Mellitus
Sponsor
Parc de Salut Mar
Enrollment
158
Locations
2
Primary Endpoint
Tolerability of the bowel preparation (analogue visual scale)
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

This trial will compare the tolerance to 2 different methods for colon cleansing before colonoscopy in diabetic patients.

Detailed Description

Consecutive diabetic patients undergoing an ambulatory colonoscopy at the participating sites will be randomized to 2 different methods of colon cleansing before the procedure. Both will be based on the oral ingestion of a fluid solution (half of it on the evening before the procedure is planned and the rest on the morning of the same day), and the main difference between them will be the volume of fluid that will be ingested in each case. Analogic visual scales and standardized questionnaires on various aspects that may influence the degree of satisfaction about the preparation will be answered by the participants and collected before the colonoscopy. The endoscopist, blinded to the preparation method, will grade the adequacy of the preparation. Adverse events will be recorded up to 1 month after the procedure

Registry
clinicaltrials.gov
Start Date
December 2, 2014
End Date
January 26, 2016
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Parc de Salut Mar
Responsible Party
Principal Investigator
Principal Investigator

Marco Antonio Alvarez Gonzalez

MD

Parc de Salut Mar

Eligibility Criteria

Inclusion Criteria

  • Patients scheduled for a diagnostic, screening or follow-up outpatient colonoscopy
  • Diabetes mellitus (being treated with insulin or any oral agent).

Exclusion Criteria

  • Unwillingness to participate.
  • Hospital admission at the time of colonoscopy.
  • Inability to follow instructions
  • Active inflammatory bowel disease
  • Previous colectomy.
  • Incomplete colonoscopies due to technical reasons or contraindication for the procedure as evaluated by the endoscopist

Arms & Interventions

PEG-ascorbate 2L

Subjects will take 2 liters of a polyethylene glycol 3500 (sodium sulphate, sodium chloride, postassium chloride), ascorbic acid and sodium ascorbate solution.

Intervention: PEG-ascorbate 2L

PEG 4L

Subjects will take 4 liters of a polyethylene glycol 4000 (sodium sulphate, sodium chloride, postassium chloride and sodium bicarbonate) solution.

Intervention: PEG 4L

Outcomes

Primary Outcomes

Tolerability of the bowel preparation (analogue visual scale)

Time Frame: 6 hours after finishing bowel preparation

Each participant will rate his/her experience in an analogue visual scale.

Secondary Outcomes

  • Adverse events(30 days after the colonoscopy)
  • Abdominal pain, nausea and bloating (analogue visual scale)(6 hours after finishing bowel preparation)
  • Efficacy of the bowel preparation (Boston Bowel Preparation Scale (BBPS)(10 minutes after the colonoscopy)
  • Acceptability of the preparation (interference with work, leisure activities or sleep questionnaire)(6 hours after finishing bowel preparation)
  • Adherence to the planned bowel cleansing method (questionnaire)(6 hours after finishing bowel preparation)
  • Ease of consumption and taste of the laxative (analogue visual scale)(6 hours after finishing bowel preparation)

Study Sites (2)

Loading locations...

Similar Trials